Argos Therapeutics Inc. (ARGS) Major Shareholder International S. Pharmstandard Acquires 31,704 Shares
Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard purchased 31,704 shares of Argos Therapeutics stock in a transaction on Friday, October 7th. The shares were acquired at an average price of $4.73 per share, for a total transaction of $149,959.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Argos Therapeutics Inc. (NASDAQ:ARGS) traded down 3.83% during trading on Thursday, hitting $4.52. The stock had a trading volume of 75,541 shares. The company’s 50 day moving average is $4.89 and its 200-day moving average is $5.91. The company’s market cap is $186.21 million. Argos Therapeutics Inc. has a 12 month low of $1.61 and a 12 month high of $13.97.
Argos Therapeutics (NASDAQ:ARGS) last released its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.05. On average, equities research analysts predict that Argos Therapeutics Inc. will post ($1.56) earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/argos-therapeutics-inc-args-major-shareholder-international-s-pharmstandard-acquires-31704-shares.html
Institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. purchased a new position in Argos Therapeutics during the second quarter valued at $137,000. California State Teachers Retirement System bought a new position in shares of Argos Therapeutics during the second quarter worth approximately $137,000. KCG Holdings Inc. bought a new position in shares of Argos Therapeutics during the second quarter worth approximately $163,000. BlackRock Investment Management LLC increased its position in shares of Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 37,818 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the last quarter. Institutional investors and hedge funds own 11.05% of the company’s stock.
A number of analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Argos Therapeutics in a research note on Friday, June 17th. Zacks Investment Research raised Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Monday, August 15th. FBR & Co dropped their price objective on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, August 11th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $11.00 price objective on shares of Argos Therapeutics in a research note on Monday, June 20th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $11.50.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.